Nuvalent (NUVL) Research & Development (2020 - 2026)
Nuvalent (NUVL) reported Research & Development of $83.61 million for Q1 2026, up 12.3% from $74.42 million a year earlier and up 23.3% from the prior quarter.
Powered by 
Analysis
Nuvalent (NUVL) Research & Development (2020 - 2026) Analysis & Trends
Over the twelve months ended Mar 31, 2026, Nuvalent's Research & Development came in at $316.16 million, up 24.7% year-over-year; for FY2025, it was $306.97 million, up 41.0% from FY2024.
- Research & Development has increased for five consecutive years, with a five-year compound annual growth rate of 81.9% (FY2020 to FY2025).
- By year, Research & Development came in at $217.77 million in FY2024 (+92.3%), $113.24 million in FY2023 (+77.7%), $63.73 million in FY2022 (+79.2%) and $35.56 million in FY2021 (+130.9%).
- Five-year quarterly Research & Development spans a low of $7.83 million in Q2 2021 and a high of $83.84 million in Q3 2025.
- Year over year, Research & Development gained in seven of the last eight quarters, with growth averaging 61.9%.
- The high point for year-over-year Research & Development in five years was Q4 2021 (growth of 180.8%); the low point was Q4 2025 (a decline of 2.3%).
- Per Business Quant data, the three quarters before Q1 2026 came in at $67.8 million (Q4 2025), $83.84 million (Q3 2025) and $80.91 million (Q2 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | 83.61 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 83.61 Mn |
| Dec 31, 2025 | 67.80 Mn |
| Sep 30, 2025 | 83.84 Mn |
| Jun 30, 2025 | 80.91 Mn |
| Mar 31, 2025 | 74.42 Mn |
| Dec 31, 2024 | 69.42 Mn |
| Sep 30, 2024 | 60.55 Mn |
| Jun 30, 2024 | 49.17 Mn |
| Mar 31, 2024 | 38.63 Mn |
| Dec 31, 2023 | 35.59 Mn |
| Sep 30, 2023 | 29.61 Mn |
| Jun 30, 2023 | 25.92 Mn |
| Mar 31, 2023 | 22.13 Mn |
| Dec 31, 2022 | 22.86 Mn |
| Sep 30, 2022 | 14.63 Mn |
| Jun 30, 2022 | 13.56 Mn |
| Mar 31, 2022 | 12.69 Mn |
| Dec 31, 2021 | 13.19 Mn |
| Sep 30, 2021 | 9.06 Mn |
| Jun 30, 2021 | 7.83 Mn |
API Access
Nuvalent Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=NUVL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "NUVL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=NUVL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();